BOSTON, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare pediatric liver disease company developing novel bile acid modulators, today announced that Bylvay (odevixibat), ...
BOSTON, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, completed an ex-U.S. commercial distributor ...
Pooled phase 3 data presented at North American Society for Pediatric Gastroenterology, Hepatology & Nutrition 2023 support the benefit-risk profile of the ileal bile acid transport inhibitor in ...
BOSTON, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced late-breaker ...
BOSTON, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced positive ...
Please provide your email address to receive an email when new articles are posted on . Odevixibat treatment reduced levels of peripheral blood autotaxin, pruritus and serum bile acid among pediatric ...
The US Food and Drug Administration (FDA) has approved odevixibat (Bylvay, Albireo Pharma), the first treatment for pruritus associated with all types of progressive familial intrahepatic cholestasis ...
Odevixibat (Bylvay, Albireo Pharma) is a selective inhibitor of the ileal bile acid transporter (IBAT). IBAT is involved in the absorption of bile acids in the small intestine for circulation back to ...
Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024 PARIS, FRANCE, 18 November, 2024 Ipsen (Euronext: IPN; ADR: IPSEY) today ...
Bylvay™ is the first and only medication approved in Canada for the treatment of both Alagille Syndrome and Progressive Familial Intrahepatic Cholestasis TORONTO, Sept. 9, 2025 /CNW/ -- Medison and ...
Odevixibat (Bylvay) reduced intense itching and serum bile acids in children with progressive familial intrahepatic cholestasis (PFIC), as detailed in the publication of the PEDFIC 1 trial results ...
WASHINGTON -- Treatment with odevixibat (Bylvay) led to early, rapid, and sustained improvements in pruritus among pediatric patients with Alagille syndrome, as well as reductions in bile acid levels, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results